-
公开(公告)号：US20230181708A1
公开(公告)日：2023-06-15
申请号：US17887444
申请日：2022-08-13
Applicant: Khloris Biosciences, Inc.
Inventor： Nigel G. Kooreman , Stephen D. Wolpe , Lynne A. Bui
CPC classification number: A61K39/001152 , A61K39/39 , A61K41/17 , A61P35/00 , A61K2039/5156 , A61K2039/5555 , A61K2039/55561 , A61K2039/55572 , A61K2039/55516 , A61K2039/55544
Abstract: In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.
-
公开(公告)号：US20220387569A1
公开(公告)日：2022-12-08
申请号：US17827957
申请日：2022-05-30
Applicant: Khloris Biosciences, Inc.
Inventor： Stephen D. Wolpe , Lynne A. Bui , Nigel G. Kooreman
Abstract: In one embodiment, the present application discloses a mammalian autologous vaccine or allogeneic vaccine comprising an effective amount of a mammalian induced pluripotent stem cells (iPSCs) obtained by reprogramming of somatic cells from a patient; wherein the autologous vaccine or the allogeneic vaccine expresses a gene selected from the group consisting of ASTE1, BIRC5, CDCA1, CDKN2A, DEPDC1, EGFR, ERBB2, FOXM1, GPC3, HJURP, HSPA8, HSP90B1, IDH1, IDO1, IGF2BP3, IMPS, KIF20A, KIF20B, MELK, MGAT5, NUF2, PMEL, RAS, TAF1B, TOMM34, TTK, TP53, VEGFR1 and VEGFR2; and wherein the autologous vaccine or the allogeneic vaccine induces an immune response from the patient for the treatment of cancer.
